The U.S. FDA approved Jazz Pharmaceuticals and Roche's combination therapy for extensive-stage small-cell lung cancer (SCLC) as first-line maintenance treatment. The approval, based on the phase III Imforte study, showed a 46% reduction in disease progression or death risk and a 27% reduction in mortality compared to atezolizumab alone. This therapy provides a novel option for patients who have not progressed after initial induction therapy with chemo-immunotherapy. This approval marks the first combination therapy for first-line maintenance in this indication, underscoring progress in addressing this aggressive cancer type.